

## DEPARTMENT OF HEALTH & HUMAN SERVICES

## PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

FOR EXPRESS MAIL:
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 402-7065

December 16, 2019

Re: Animal Welfare Assurance #A3343-01 (OLAW Case 2R)

Dr. Giulio Draetta
Chief Scientific Officer
University of Texas MD Anderson Center
1515 Halcombe Boulevard — (b) (4)
Houston, Texas 77030

Dear Dr. Draetta,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your December 11, 2019 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at MD Anderson Cancer Center.

According to the information provided, this Office understands that the MD Anderson's Animal Care and Use Committee (ACUC) determined that instances of noncompliance occurred with respect to: multiple cages of mice found with bleeding digits after an unapproved toe clipping procedure that occurred on October 22, 2019. The letter states that 5 mice required medical intervention to achieve hemostasis and received analgesics. Corrective actions included:

- Veterinarian meeting with the responsible individual to receive additional training on proper specimen collection.
- 2) The investigator was counseled on the importance of adhering to the approved IACUC protocol. The IACUC reviewed the incidence and corrective actions at the meeting held on November 19, 2019. The committee considered the actions sufficient to prevent any future recurrence of this matter. The letter states that it was determined that the matter did not have any effect on the PHS-supported animal activity.

Based on its assessment of this explanation, OLAW understands that MD Anderson Cancer Center has implemented appropriate measures to correct and prevent recurrences of these problems and is now compliant with provisions of the PHS Policy. We appreciate being informed of these matters and find no cause for action by this Office.

Sincerely,
(b) (6)

Jacquelyn T. Tubbs, DVM Veterinary Medical Officer Division of Compliance Oversight Office of Laboratory Animal Welfare

cc: IACUC contact

A3343-2R



Making Cancer History\*

Giulio Draetta, M.D., Ph.D. Chief Sclentific Officer 1515 Holcombe Boulevard Unit 1640 Houston, Texas 77030 T 713-563-5681

December 11, 2019

## VIA ELECTRONIC SUBMISSION

olawdco@mail.nih.gov

Brent C. Morse, DVM, DACLAM
Director, Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
Rockledge 1, Suite 360, MSC 7982
6705 Rockledge Drive
Bethesda, MD 20892-7982

Re:

Reportable Incident; Animal Assurance # A3343-01

MDA internal reference # HFG3-1020-001

Funding: NCI 5R35CA197566-02

Dear Dr. Morse,

As Institutional Official for The University of Texas MD Anderson Cancer Center (MD Anderson), it is my duty to report to you a finding of a serious deviation from the provisions of the *Guide for the Care and Use of Laboratory Animals* (Guide).

A failure to adhere to IACUC approved protocols.

On October 22, 2019, multiple cages of adult mice were found with bleeding digits after an unapproved toe clipping procedure. Five of these mice required cauterization of the vessels to stop the bleeding and given analgesics.

The animal manipulator involved met with a veterinarian in the Department of Veterinary Medicine and Surgery and received additional training on proper specimen collection. The Principal Investigator was counseled on December 6, 2019 regarding the importance of adhering to the approved IACUC protocol.

MD Anderson's Institutional Animal Care and Use Committee (IACUC) reviewed the incident and corrective and preventive actions at its fully convened meeting on November 19, 2019. The IACUC determined that the corrective and preventive actions were sufficient to prevent any future recurrence of this matter. The IACUC also determined that the matter did not have any effect on the PHS-supported animal research activity.

MD Anderson is committed to assuring compliance with the PHS policy and the Guide, and to maintaining proper measures and procedures to ensure the appropriate care and use of all animals involved in research. I will be happy to respond to any additional questions you may have regarding this report.

Sincerely,

(b) (6)

Giulio Draetta, M.D., Ph.D.
Institutional Official, Chief Scientific Officer
MD Anderson Cancer Center
1515 Holcombe Blvd.
(b) (4)
Houston, TX 77030

cc:

Jim Bankson, Ph.D., IACUC Chair

(b) (6)

Gaylen Howell, M.S., M.B.A. Director, Research Oversight and Integrity, Institutional Compliance Office

## Wolff, Axel (NIH/OD) [E]

From:

OLAW Division of Compliance Oversight (NIH/OD)

Sent:

Thursday, December 12, 2019 9:37 AM

To:

(b) (6)

Cc:

OLAW Division of Compliance Oversight (NIH/OD)

Subject:

RE: MD Anderson Incident Report # HFG3-1020-001 (A3343-01)

Thank you for this report,

(b) (6) We will send a response soon.

Axel Wolff, M.S., D.V.M. Deputy Director, OLAW

From:

(b) (6)

Sent: Wednesday, December 11, 2019 4:59 PM

To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>

Cc: Howell, Gaylen W < gwhowell@mdanderson.org>; Bankson, Jim < jbankson@mdanderson.org>;

(b) (6)

(b) (6)

Subject: MD Anderson Incident Report # HFG3-1020-001 (A3343-01)

Dear Dr. Morse,

Please find attached our final report for an incident that occurred at MD Anderson Cancer Center. Please do not hesitate to contact me if you have any questions.

Thank you,

(b) (6)





Making Cancer History

The information contained in this e-mail message may be privileged, confidential, and/or protected from disclosure. This e-mail message may contain protected health information (PHI); dissemination of PHI should comply with applicable federal and state laws. If you are not the intended recipient, or an authorized representative of the intended recipient, any further review, disclosure, use, dissemination, distribution, or copying of this message or any attachment (or the information contained therein) is strictly prohibited. If you think that you have received this e-mail message in error, please notify the sender by return e-mail and delete all references to it and its contents from your systems.